Codon-specific translation reprogramming promotes resistance to targeted therapy
Abstract
Reprogramming of mRNA translation has a key role in cancer development and drug resistance 1 . However, the molecular mechanisms that are involved in this process remain poorly understood. Wobble tRNA modifications are required for specific codon decoding during translation 2,3. Here we show, in humans, that the enzymes that catalyse modifications of wobble uridine 34 (U 34) tRNA (U 34 enzymes) are key players of the protein synthesis rewiring that is induced by the transformation driven by the BRAF V600E oncogene and by resistance to targeted therapy in melanoma. We show that BRAF V600E -expressing melanoma cells are dependent on U 34 enzymes for survival, and that concurrent inhibition of MAPK signalling and ELP3 or CTU1 and/or CTU2 synergizes to kill melanoma cells. Activation of the PI3K signalling pathway, one of the most common mechanisms of acquired resistance to MAPK therapeutic agents, markedly increases the expression of U 34 enzymes. Mechanistically, U 34 enzymes promote glycolysis in melanoma cells through the direct, codon-dependent, regulation of the translation of HIF1A mRNA and the maintenance of high levels of HIF1α protein. Therefore, the acquired resistance to anti-BRAF therapy is associated with high levels of U 34 enzymes and HIF1α. Together, these results demonstrate that U 34 enzymes promote the survival and resistance to therapy of melanoma cells by regulating specific mRNA translation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ELP proteins contribute to EGFR inhibitor resistance in breast cancer cells by promoting MCL1 synthesis.
“and that ELPs contribute to EGFR inhibitor resistance in breast cancer cells by promoting MCL1 synthesis (71).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [71]
The citation lists haven’t been fetched yet
References 36 · Cited by 271
- Authors
- Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., Ghesquière, B., Karim, L., Charloteaux, B., Jamart, D., Florin, A., Lambert, C., Rorive, A., Jerusalem, G., Leucci, E., Dewaele, M., Vooijs, M., Leidel, S. A., Georges, M., Voz, M., Peers, B., Büttner, R., Marine, J.-C., Chariot, A., & Close, P.
- Affiliations
- University of Liège (BE)
- VIB-KU Leuven Center for Cancer Biology (BE)
- University Hospital Cologne (DE)
- University of Münster (DE)
- Maastricht University (NL)
- Corresponding author
- Close, Pierre
- ORCID
- Rapino, Francesca
- Delaunay, Sylvain
- Rambow, Florian
- Zhou, Zhaoli
- Tharun, Lars
- Sin, Olga
- Shostak, Kateryna
- Schmitz, Sebastian
- Ghesquière, Bart
- Florin, Alexandra
- Leucci, Eleonora
- Dewaele, Michael
- Vooijs, Marc
- Leidel, Sebastian A.
- Georges, Michel
- Voz, Marianne
- Peers, Bernard
- Büttner, Reinhard
- Marine, Jean-Christophe
- Chariot, Alain
- Close, Pierre
- Venue
- Nature
- Published
- 2018-06-20
- Volume
- 558
- Issue
- 7711
- Pages
- 605-609
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2808878318
- Cited by
- 271
- References
- 36
- Citations by year
- 2026: 26 · 2025: 36 · 2024: 32 · 2023: 30 · 2022: 26 · 2021: 44 · 2020: 30 · 2019: 35 · 2018: 12
- FWCI
- 10.76
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-11-11)
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- BRAF V600E mutation, melanoma, acquired drug resistance, MAPK inhibitor resistance, PI3K signaling, glycolysis, Elp3, cancer metabolism
- MeSH terms
- Mechanistic Target of Rapamycin Complex 2, Vemurafenib, Animals, Carrier Proteins, Codon, Female, Humans, Male, Melanoma, Melanoma, Experimental, Phosphorylation, RNA, Messenger, RNA, Transfer, Protein Biosynthesis, Uridine, Zebrafish, Signal Transduction, Mice, SCID, Mice, Inbred NOD, Drug Resistance, Neoplasm, Transcriptional Elongation Factors, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review